Santen Pharmaceutical Co. Ltd
Santen Pharmaceutical Co., Ltd. engages in the research and development, manufacturing, and marketing of pharmaceuticals and medical devices in Japan, China, Asia, Europe, the Middle East, Africa, and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker for the treatment of glaucoma and ocular hypertensio… Read more
Santen Pharmaceutical Co. Ltd (SNPHF) - Net Assets
Latest net assets as of March 2025: $285.18 Billion USD
Based on the latest financial reports, Santen Pharmaceutical Co. Ltd (SNPHF) has net assets worth $285.18 Billion USD as of March 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($409.28 Billion) and total liabilities ($124.10 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $285.18 Billion |
| % of Total Assets | 69.68% |
| Annual Growth Rate | 4.96% |
| 5-Year Change | -7.12% |
| 10-Year Change | 9.68% |
| Growth Volatility | 8.18 |
Santen Pharmaceutical Co. Ltd - Net Assets Trend (2005–2025)
This chart illustrates how Santen Pharmaceutical Co. Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Santen Pharmaceutical Co. Ltd (2005–2025)
The table below shows the annual net assets of Santen Pharmaceutical Co. Ltd from 2005 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | $285.18 Billion | -6.61% |
| 2024-03-31 | $305.37 Billion | +4.12% |
| 2023-03-31 | $293.30 Billion | -12.93% |
| 2022-03-31 | $336.84 Billion | +9.70% |
| 2021-03-31 | $307.05 Billion | +1.48% |
| 2020-03-31 | $302.56 Billion | +3.41% |
| 2019-03-31 | $292.57 Billion | +1.74% |
| 2018-03-31 | $287.56 Billion | +13.26% |
| 2017-03-31 | $253.88 Billion | -2.36% |
| 2016-03-31 | $260.01 Billion | +22.77% |
| 2015-03-31 | $211.78 Billion | +16.87% |
| 2014-03-31 | $181.21 Billion | +9.74% |
| 2013-03-31 | $165.13 Billion | +0.16% |
| 2012-03-31 | $164.86 Billion | +5.41% |
| 2011-03-31 | $156.40 Billion | +13.66% |
| 2010-03-31 | $137.60 Billion | +9.76% |
| 2009-03-31 | $125.37 Billion | -1.38% |
| 2008-03-31 | $127.12 Billion | -1.19% |
| 2007-03-31 | $128.65 Billion | +8.44% |
| 2006-03-31 | $118.64 Billion | +9.61% |
| 2005-03-31 | $108.24 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Santen Pharmaceutical Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 138.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $228.29 Billion | 79.75% |
| Common Stock | $8.81 Billion | 3.08% |
| Other Components | $49.15 Billion | 17.17% |
| Total Equity | $286.24 Billion | 100.00% |
Santen Pharmaceutical Co. Ltd Competitors by Market Cap
The table below lists competitors of Santen Pharmaceutical Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Quálitas Controladora S.A.B. de C.V
OTCGREY:QUCOF
|
$3.47 Billion |
|
PrairieSky Royalty Ltd
PINK:PREKF
|
$3.48 Billion |
|
Shenzhen Sunlord Electronics Co Ltd
SHE:002138
|
$3.48 Billion |
|
Minor International Public Company Limited
PINK:MINOF
|
$3.48 Billion |
|
CALIFORNA RESOURC. DL-01
F:1CLD
|
$3.47 Billion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
$3.47 Billion |
|
Avanza Bank Holding AB (publ)
ST:AZA
|
$3.47 Billion |
|
Vietnam Rubber Group Ltd
VN:GVR
|
$3.47 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Santen Pharmaceutical Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 306,055,000,000 to 286,242,000,000, a change of -19,813,000,000 (-6.5%).
- Net income of 36,256,000,000 contributed positively to equity growth.
- Dividend payments of 12,111,000,000 reduced retained earnings.
- Share repurchases of 37,883,000,000 reduced equity.
- Other comprehensive income decreased equity by 48,412,000,000.
- Other factors increased equity by 42,337,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $36.26 Billion | +12.67% |
| Dividends Paid | $12.11 Billion | -4.23% |
| Share Repurchases | $37.88 Billion | -13.23% |
| Other Comprehensive Income | $-48.41 Billion | -16.91% |
| Other Changes | $42.34 Billion | +14.79% |
| Total Change | $- | -6.47% |
Book Value vs Market Value Analysis
This analysis compares Santen Pharmaceutical Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.01x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-03-31 | $246.90 | $10.53 | x |
| 2006-03-31 | $273.33 | $10.53 | x |
| 2007-03-31 | $296.12 | $10.53 | x |
| 2008-03-31 | $293.31 | $10.53 | x |
| 2009-03-31 | $294.68 | $10.53 | x |
| 2010-03-31 | $323.17 | $10.53 | x |
| 2011-03-31 | $365.73 | $10.53 | x |
| 2012-03-31 | $378.07 | $10.53 | x |
| 2013-03-31 | $390.86 | $10.53 | x |
| 2014-03-31 | $437.75 | $10.53 | x |
| 2015-03-31 | $510.49 | $10.53 | x |
| 2016-03-31 | $625.55 | $10.53 | x |
| 2017-03-31 | $614.41 | $10.53 | x |
| 2018-03-31 | $700.77 | $10.53 | x |
| 2019-03-31 | $714.05 | $10.53 | x |
| 2020-03-31 | $756.68 | $10.53 | x |
| 2021-03-31 | $768.22 | $10.53 | x |
| 2022-03-31 | $842.76 | $10.53 | x |
| 2023-03-31 | $758.81 | $10.53 | x |
| 2024-03-31 | $831.36 | $10.53 | x |
| 2025-03-31 | $818.55 | $10.53 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Santen Pharmaceutical Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 12.67%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 12.09%
- • Asset Turnover: 0.73x
- • Equity Multiplier: 1.43x
- Recent ROE (12.67%) is above the historical average (9.81%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 10.18% | 11.89% | 0.66x | 1.29x | $198.10 Million |
| 2006 | 10.98% | 13.23% | 0.65x | 1.27x | $1.16 Billion |
| 2007 | 10.22% | 13.08% | 0.63x | 1.24x | $282.50 Million |
| 2008 | 9.95% | 12.23% | 0.66x | 1.23x | $-61.80 Million |
| 2009 | 8.07% | 9.96% | 0.67x | 1.20x | $-2.41 Billion |
| 2010 | 13.61% | 16.93% | 0.66x | 1.21x | $4.96 Billion |
| 2011 | 13.64% | 19.25% | 0.60x | 1.18x | $5.69 Billion |
| 2012 | 10.41% | 15.00% | 0.58x | 1.21x | $673.90 Million |
| 2013 | 10.00% | 13.87% | 0.60x | 1.21x | $6.90 Million |
| 2014 | 10.88% | 13.26% | 0.64x | 1.28x | $1.60 Billion |
| 2015 | 11.35% | 14.85% | 0.53x | 1.44x | $2.85 Billion |
| 2016 | 20.53% | 27.33% | 0.55x | 1.37x | $27.37 Billion |
| 2017 | 8.58% | 10.91% | 0.62x | 1.28x | $-3.58 Billion |
| 2018 | 12.34% | 15.68% | 0.58x | 1.36x | $6.68 Billion |
| 2019 | 10.98% | 13.65% | 0.60x | 1.34x | $2.86 Billion |
| 2020 | 7.80% | 9.78% | 0.59x | 1.35x | $-6.67 Billion |
| 2021 | 2.22% | 2.74% | 0.62x | 1.31x | $-23.93 Billion |
| 2022 | 8.06% | 10.22% | 0.58x | 1.36x | $-6.53 Billion |
| 2023 | -5.08% | -5.36% | 0.66x | 1.43x | $-44.35 Billion |
| 2024 | 8.70% | 8.82% | 0.69x | 1.42x | $-3.96 Billion |
| 2025 | 12.67% | 12.09% | 0.73x | 1.43x | $7.63 Billion |
Industry Comparison
This section compares Santen Pharmaceutical Co. Ltd's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $308,328,125,500
- Average return on equity (ROE) among peers: 18.93%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Santen Pharmaceutical Co. Ltd (SNPHF) | $285.18 Billion | 10.18% | 0.44x | $3.47 Billion |
| AbbVie Inc (ABBV) | $13.10 Billion | 35.24% | 10.50x | $390.88 Billion |
| Astellas Pharma Inc (ALPMF) | $1.06 Trillion | 7.80% | 0.36x | $16.93 Billion |
| Amgen Inc (AMGN) | $20.39 Billion | 20.58% | 0.79x | $196.91 Billion |
| Amarin Corporation PLC (AMRN) | $28.90 Million | 14.19% | 0.23x | $303.32 Million |
| AstraZeneca PLC (AZN) | $48.72 Billion | 21.05% | 1.34x | $296.35 Billion |
| Bayer AG (BAYZF) | $31.90 Billion | 14.21% | 1.58x | $21.61 Billion |
| Biogen Inc (BIIB) | $325.20 Million | 9.96% | 0.10x | $26.81 Billion |
| Bristol-Myers Squibb Company (BMY) | $5.08 Billion | 14.69% | 0.67x | $121.36 Billion |
| Chugai Pharmaceutical Co. Ltd (CHGCF) | $1.90 Trillion | 20.37% | 0.16x | $28.30 Billion |
| Cosmo Pharmaceuticals N.V (CMOPF) | $220.16 Million | 31.22% | 0.10x | $529.97 Million |